Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 24

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 24
---
 the agreement, and (ii) research activities continued thereafter
with the knowledge and involvement of Yissum and University personnel. The parties are currently engaged in discussions to resolve this
disagreement, but there can be no assurance that these discussions will be successful.

The Company intends to evaluate results from
a planned large-animal safety study — originally scheduled for the fourth quarter of 2025 and now rescheduled to the first half
of 2026 — before determining whether to exercise the license option. As of the date of this prospectus, initiation of this study
has been delayed due to the non-receipt of what the Company considers to be the contractually required final scientific report.

If we are unable to reach an amicable resolution
with Yissum that preserves our right to exercise the option, or if we ultimately elect not to exercise the option based on the results
of the large animal study, our development pipeline would exclude the Nano-Candesartan product candidate. Such an outcome would remove
this candidate from our development pipeline and could require us to evaluate whether the carrying value of intangible assets associated
with the ARB program should be impaired. Any such impairment, as well as the loss of expected future development opportunities, could
affect our business, financial condition, and prospects.

Our Chief Financial Officer may face competing demands on his time and attention.

Our Chief Financial
Officer, Arie Gordashnikov, plans to devote time to our business, but does not intend to focus exclusively on us. Mr. Gordashnikov also
serves in the same capacity for other companies. He may divide his time among these entities and us. Because our Chief Financial Officer
manages other businesses, he will not fully dedicate himself to advancing our business, financial condition, or operational results which
could hurt our business, financial condition and results of operations.

We are dependent upon our officers and directors and their loss, or a reduction in the amount of time they can dedicate to our initial business combination, could adversely affect our ability to operate.

Our operations are dependent
upon a relatively small group of individuals and, in particular, our officers and directors. We believe that our success depends on the
continued service of our officers and directors. In addition, our officers and directors are not required to commit any specified amount
of time to our affairs and, accordingly, will have conflicts of interest in allocating their time among various business activities,
including identifying potential business combinations and monitoring the related due diligence. We do not have